Aion Therapeutic Provides Default Status Update
Aion Therapeutic Provides Default Status Update
Toronto, Ontario--(Newsfile Corp. - October 25, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022, September 26, 2022 and October 11, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").
安大略省多倫多-(Newsfile Corp.-2022年10月25日)-Aion治療公司(CSE：AION) ("Aion治療“或”公司“)宣佈，繼2022年9月13日、2022年9月26日和2022年10月11日的新聞稿之後，它將根據國家政策12-203中規定的替代信息準則提供一份默認狀態報告-針對持續披露違約的停止交易指令 ("NP 12-203").
On August 30, 2022, the Company announced (the "Default Announcement") that it had not filed its annual financial statements and management discussion and analysis for the year ended April 30, 2022, together with the related certification of filings under National Instrument 52-109 - Certification of Disclosure in Issuers' Annual and Interim Filings (collectively, the "Continuous Disclosure Documents") by the prescribed deadline of August 29, 2022.
2022年8月30日，本公司宣佈(《默認公告“)它沒有提交截至2022年4月30日的年度財務報表和管理層討論和分析，以及根據國家文書52-109提交的相關證明-發行人在年度和中期申報文件中披露信息的證明(總而言之，“持續披露文件“)在規定的截止日期2022年8月29日之前。
Except as discussed below, there have been no material changes to the information contained in the Default Announcement or any other changes required to be disclosed under NP 12-203.
除以下討論外，默認公告所載資料並無重大變動，或NP12-203規定須予披露的任何其他變動。
The Company anticipates that the Continuous Disclosure Documents will be filed prior to October 31, 2022. The Company will continue to provide bi-weekly updates, as contemplated by NP 12-203, until the Continuous Disclosure Documents have been filed. In the event that the Company does not file the Continuous Disclosure Documents by October 31, 2022 the Canadian Securities Regulatory Authorities may impose an issuer cease trade order on the outstanding securities of the Company. The Company intends to satisfy the provisions of the Alternative Information Guidelines during the period it remains in default of the filing requirements.
公司預計持續披露文件將在2022年10月31日之前提交。公司將繼續按照NP 12-203的規定，每兩週更新一次，直到持續披露文件提交完畢。如果公司沒有在2022年10月31日之前提交持續披露文件，加拿大證券監管機構可能會對公司的未償還證券實施發行人停止交易令。本公司打算在其仍未遵守申報要求的期間內，滿足替代信息指南的規定。
About Aion Therapeutic Inc.
Aion治療公司簡介
Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.
Aion治療公司通過其全資子公司AI PharmPharmticals牙買加有限公司從事研發、治療、數據挖掘和最先進的人工智能(機器學習)技術業務，專注於在合法環境下開發組合藥品、營養食品和化粧品，利用大麻(大麻)、迷幻蘑菇(裸蓋菇素)、真菌(食用菌)、天然迷幻製劑(Ayahuasca)和其他藥用植物的化合物進行此類發現。此外，Aion治療公司正在創建與其發現相關的強大的國際知識產權組合。
For further information, please contact:
如需更多信息，請聯繫：
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
Aion治療公司
格雷厄姆·西蒙茲
執行副主席兼首席執行官
(416) 843-2881
DISCLAIMER & READER ADVISORY
免責聲明和讀者建議
Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.
本新聞稿中陳述的某些信息可能包含前瞻性信息，這些信息涉及大量已知和未知的風險和不確定性。這些前瞻性信息受到許多風險和不確定性的影響，其中某些風險和不確定性不是公司所能控制的，包括但不限於一般經濟條件、行業條件和對監管批准的依賴的影響。請讀者注意，編制這類信息時使用的假設雖然在編制時被認為是合理的，但可能被證明是不準確的，因此不應過度依賴前瞻性信息。雙方不承擔更新前瞻性信息的義務，除非適用的證券法另有要求。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。